EA5

Phase 1Biologic

SShanghai Lanyi Therapeutics Co., Ltd.

EA5 is one of 18 biologic programs targeting Generalized Myasthenia Gravis (gMG). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Generalized Myasthenia Gravis (gmg)Not yet recruiting

Paroxysmal Nocturnal HemoglobinuriaRecruiting

Generalized Myasthenia Gravis (gmg)Phase 1

Not yet recruiting

Paroxysmal Nocturnal HemoglobinuriaPhase 1

Recruiting

Competition

Competitive Landscape

17 competitors in Paroxysmal Nocturnal Hemoglobinuria

#DrugCompanyPhaseTrials

Soliris

AstraZeneca

Approved

25 2

Ultomiris

AstraZeneca

Approved

12 3

Fabhalta

Novartis

Phase 3

2 4

VEOPOZ

Regeneron

Phase 3

7 5

PIASKY

Roche

Phase 3

3 6

NTQ5082

NNanjing Chia-tai Tianqing Pharmaceutical

Phase 3

2 7

Cemdisiran

Regeneron

Phase 3

7 8

NM8074

NNovelMed Therapeutics

Phase 2

1 9

HRS-5965

CChengdu Suncadia Medicine Co., Ltd.

Phase 3

3 10

ADX-038

AADARx Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Generalized Myasthenia Gravis (gmg)

NCT07818291

Clinical

Trials by Indication[1]

Adult Subject1 trial

A Phase Ia Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of EA5 in Healthy Adult Subjects

Completed·SShanghai Lanyi Therapeutics Co., Ltd.·Phase 1·NCT07256288·28 enrolled

Paroxysmal Nocturnal Hemoglobinuria1 trial

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recruiting·SShanghai Lanyi Therapeutics Co., Ltd.·Phase 1·NCT07256301·24 enrolled

Generalized Myasthenia Gravis (gMG)1 trial

An Open-label, Dose-escalation Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Doses of EA5 Humanized Monoclonal Antibody in Adult Patients With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis

Not yet recruiting·SShanghai Lanyi Therapeutics Co., Ltd.·Phase 1·NCT07818291·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for EA5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EA5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EA5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Lanyi Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SShanghai Lanyi Therapeutics Co., Ltd.

EA5

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Adult Subject1 trial

Paroxysmal Nocturnal Hemoglobinuria1 trial

Generalized Myasthenia Gravis (gMG)1 trial

References

Drug Info

Quick Facts

Related News